NLBNPIT22TS9 20240920 250 (P22TS9) Actualités

Form 8-K - Current report

U.S. FDA Grants Tentative Approval of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

FDA confirmed that the amendment to add PH-ILD to the YUTREPIA NDA was proper and that application otherwise...

Liquidia Announces Poster Presentations at the PHA 2024 International PH Conference and Scientific Sessions

MORRISVILLE, N.C., Aug. 16, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), announced today the...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Liquidia Corporation Reports Second Quarter 2024 Financial Results and Provides Corporate Update

MORRISVILLE, N.C., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical...

Liquidia Corporation to Report Second Quarter 2024 Financial Results on August 7, 2024

MORRISVILLE, N.C., July 31, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form EFFECT - Notice of Effectiveness

Liquidia Announces Poster Presentations at the 7th World Symposia on Pulmonary Hypertension (WSPH)

Liquidia to feature two live posters sessions and five encore presentations covering its investigational...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities